News | August 12, 2010

Catheter-Deployed Device Reduces LV Volume in Heart Failure Patients

August 12, 2010 – A 52-year-old male heart failure patient in Krakow, Poland, became the first human to receive the PliCath HF System for an epicardial catheter-based ventricular reconstruction (ECVR). The device is designed to treat heart failure (HF) by reducing the enlarged left ventricle (LV) through an anchoring system that is delivered across the cardiac chambers.

By pulling nonadjacent walls of the heart into contact, intervening scar tissue that resulted from a previous heart attack is excluded. It has been known for decades that enlarged hearts are not optimal and the reduction in the size of the LV allows the heart to maintain adequate cardiac output without working so hard.

Lead surgeon, professor Jerzy Sadowski of the Pope John Paul II Hospital, Jagiellonian University in Krakow, expressed great optimism about the device. “The BioVentrix PliCath HF device performed as it was designed. This technology allowed us to perform major reconstruction of the LV on a beating heart in a matter of minutes without incisions. The patient is recovering well. This device has great promise and should help improve the quality of life of our patients suffering from heart failure.”

The patient’s heart size was decreased by 40 percent, while the ejection fraction (EF), the percentage of blood volume ejected from the ventricle after contraction, increased by 15 percent. In extensive animal studies, the PliCath HF System improved the EF by 13 percent; the end diastolic volume by 18 percent; and the end systolic volume (the fully contracted part of the cardiac cycle) by 35 percent. Based on the outcome of this first procedure, it appears that similar results can be achieved in humans. Improvements of this magnitude in the heart size are expected to have a significant clinical effect, since there would be a decrease in the stretching of the remaining heart muscle, allowing it to pump with reduced strain.

“Heart failure, not unlike obesity, has become a problem of epidemic proportions. The reduction in heart size that this device can achieve is the cardiac equivalent of a 40 percent weight loss in a morbidly overweight population,” said Ken Miller, president and CEO of BioVentrix. “In the U.S., nearly 70 percent of the 5 million heart failure patients develop the disease because of a scar on their ventricle from a previous heart attack. This minimally-invasive device will extend effective treatment to a large group of patients where none is currently available.”

The PliCath HF System is an investigational device and is limited by United States law to investigational use.

For more information: www.bioventrix.com

Related Content

Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Aug.
Wearable monitors create patient generated health data, PGHD, that can help prevent acute care episodes in heart failure.

Wearable monitoring devices may offer a new tool to help prevent acute care episodes in heart failure.

Feature | Heart Failure| July 25, 2017 | Lola Koktysh
Despite their best efforts, many patients tend to develop heart failure after an acute event (e.g., a heart attack or
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT)| July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Hitachi and West Virginia University Partner to Advance Left Ventricular Mechanical Function Evaluation
News | Cardiovascular Ultrasound| July 21, 2017
Hitachi Healthcare and the West Virginia University Heart and Vascular Institute announced the formation of a new...
Hospital Readmissions Analysis Across All Ages, Insurance Types Identifies High-Risk Groups
News | Business| July 20, 2017
July 20, 2017 — Clinician-researchers at Beth Israel Deaconess Medical Center (BIDMC) recently published a first-of-i
Sponsored Content | Videos | Cardiovascular Surgery| July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients
News | Heart Failure| July 14, 2017
A review appearing in the July 18 issue of the Journal of the American College of Cardiology (JACC) discusses current...
Overlay Init